TuHURA Biosciences, Inc./NV 8-K

What Happened

• On May 15, 2026 TuHURA Biosciences, Inc. (HURA) announced and filed a press release reporting its financial results for the three months ended March 31, 2026 and provided a corporate update (Item 2.02). The press release is attached to the Form 8‑K as Exhibit 99.1.
• The company also furnished an investor presentation under Regulation FD (Item 7.01), which is included as Exhibit 99.2 and may be used in meetings with investors, analysts, or others and updated over time.
• The Form 8‑K was signed by CFO Dan Dearborn and filed on May 15, 2026.

Key Details

• Filing date: May 15, 2026 (Form 8‑K Items 2.02 and 7.01).
• Press release reporting quarterly results for the period ended March 31, 2026 attached as Exhibit 99.1.
• Investor Presentation furnished as Exhibit 99.2 and subject to updates (Regulation FD disclosure).
• Form signed by Chief Financial Officer Dan Dearborn.

Why It Matters

• This filing is the company’s formal release of its quarterly earnings and corporate update; investors should review the attached press release and investor presentation for details on results, revenue, expenses, pipeline progress, or guidance.
• The investor presentation may provide updated commercial or clinical program highlights and is the primary material the company may use in investor communications going forward.
• Because the filing contains the official quarterly results and Reg FD materials, it can drive near-term market reaction and informs shareholder assessments of TuHURA’s recent performance.